Clinical Research Directory
Browse clinical research sites, groups, and studies.
Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis
Sponsor: Ron Beloosesky MD
Summary
The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE. The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.
Official title: Apixaban Versus Enoxaparin for Thromboprophylaxis After Delivery
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-07-01
Completion Date
2027-04-01
Last Updated
2026-07-21
Healthy Volunteers
No
Conditions
Interventions
Apixaban
Apixaban. 2.5 mg administered orally twice a day
Enoxaparin
Enoxaparin 40 mg (or 60 mg for weight \> 91 kg) administered subcutaneously once a day